Table 1.
Baseline characteristics of patients in the INTERMACS registry and in landmark clinical trials who received durable axial flow LVADs.
Fig 1.
Percentages of axial flow LVAD recipients 2010–2015 meeting key clinical trial exclusion criteria.
†Not on Warfarin.
Table 2.
Outcomes at 2 years post implantation for axial flow LVADs placed 2010–2015 compared with published clinical trials.
Fig 2.
Survival estimates at 2 years according to key patient criteria among axial flow LVAD recipients enrolled in INTERMACS between 2010–2015.
N shows number of patients in each sub-group. Points in the plot shows survival probability at 2y; error bars show 95% CI. Numerical estimate and 95% CI are shown with Log-rank test p-value.
Fig 3.
Kaplan-Meier survival estimates at 2 years for high risk interventions 48 hours prior to LVAD implantation among axial flow LVAD recipients enrolled in INTERMACS between 2010–2015.
Fig 4.
Kaplan-Meier survival estimates at 2 years according to clinical trial exclusion criteria among axial flow LVAD recipients enrolled in INTERMACS between 2010–2015.
Fig 5.
Competing risks of outcomes between real world LVAD patients who would and would not qualify for landmark clinical trials.